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Introduction
Prostate cancer (PCa) has a propensity to metastasize to bone. Development of bone metastases substantially shortens survival time of men with PCa and remains a major challenge in the treatment of PCa. The mechanisms that lead to the preferential growth of PCa in bone are not known. Bone metastasis from PCa typically exhibits osteoblastic lesions (1) . In the histopathologic analysis of PCa bone metastases, a substantial increase in the numbers of osteoblasts and bone matrix adjacent to PCa cells are often seen. While metastases have an overall bone-forming phenotype, the clinical presentation of PCa bone metastasis suggests that it is a heterogeneous disease that also involves osteoclasts (2, 3) .
The complex interactions of tumor cells with osteoblasts, osteoclasts and other cells suggest that PCa cells secrete multiple factors that alter the bone microenvironment and stimulate osteoblast proliferation and/or differentiation at the sites of skeletal metastasis (4) .
Identification of factors that are involved in the osteoblastic bone lesions will uncover targets for therapy. However, this has been difficult due to anatomic inaccessibility, and the small amount of tumor in biopsies from bone metastasis is not sufficient for biochemical analysis.
Recently, two bone metastasis-derived xenografts, MDA-PCa-118b and MDA-PCa-133, have been generated, and they provide sufficient material for the analysis of the paracrine factors that play a role in PCa progression in bone. MDA-PCa-118b (PCa-118b) xenograft exhibits characteristics seen in patients with PCa in bone, e.g., a strong osteogenic phenotype when implanted into mouse femurs (5) . Interestingly, PCa-118b induced new bone formation even when implanted subcutaneously (5) . On the other hand, the MDA-PCa-133 (PCa-133) xenograft proliferates when implanted subcutaneously, but does not induce bone formation. The difference in the bone forming activity of these two xenografts reflects the heterogeneous nature of PCa bone metastases (2) .
In this study, we identified the factors secreted by these two xenografts using an antibody array that detects cytokines in the conditioned medium. We found that the osteogenic PCa-118b xenograft not only expresses higher levels of osteogenic factors, e.g., were generated by implanting fragments (less than 1 mm 3 ) of tumors subcutaneously into SCID mouse. The tumors were allowed to grow until they reached the size of 500 mm 3 , dissected, weighed, cut into small pieces, and suspended (250 mg wet weight per ml medium) in BGJb medium (Invitrogen) with antibiotics. The conditioned media were collected every 24 hrs for two days, spun to clarify and stored at -80 o C.
Materials and Methods

Materials
Assessment of chemokines in conditioned media. Chemokines and cytokines in the conditioned media were assessed by using RayBio Human Cytokine Antibody Array C (RayBiotech, Norcross, GA) (Membranes VI and VII) according to the manufacturer's instructions. The signal intensity of each spot was quantified by Image J. The signal intensity of the negative control was subtracted from each spot. The experiments were performed three times using conditioned medium from three different batches of xenograft tumors. BMP-4 or BMP-6 levels were measured using ELISA kits (RayBiotech, Norcross,
GA).
Reverse transcription and quantitative PCR analysis. Total RNA was extracted from PCa118b or PCa-133 using RNeasy mini kit (Qiagen). The relative mRNA level for each gene was quantified by real-time RT-PCR with SYBR Green (Applied Biosystems), using GAPDH as a control.
Measurement of luciferase and alkaline phosphatase activities in calvarial osteoblasts.
The transgenic mice harboring luciferase transgene (Col-luc mice) was described previously (6) . Calvarial osteoblasts from Col-luc mice or CD1 mice were incubated with conditioned medium from PCa-118b or PCa-133 with or without neutralizing antibody or LDN-193189 for three days. Cells were lysed and the luciferase activity assessed (Promega, Cat. No. E1501). Alkaline phosphatase activity was measured using p-nitrophenyl phosphate liquid substrate system (Sigma-Aldrich).
Measurement of BMP reporter activity. C2C12 cells stably expressing a BMP-responsive
Id1 promoter fused to a luciferase reporter gene (C2C12/BRA) was kindly provided by Dr. Statistical analyses were performed using Student's t-test (two-tailed, paired). p values less than 0.05 were considered significant. Figure 1A ).
Results
PCa
MicroCT analysis showed heterogeneous mineralization with various densities within the tumor ( Figure 1A ). In contrast, the femur/tibia bone exhibits uniform and much higher density than those in PCa-118b. Calcein labeling demonstrates that the newly formed bone is irregular. In contrast, the PCa-133 xenograft did not induce bone formation ( Figure 1B ). expression of cytokines in the conditioned medium from PCa-118b and PCa-133 xenografts, using the Human Cytokine Antibody Array that detects 120 cytokines and growth factors.
Cytokine Array Analysis of Conditioned
BMPs and FGFs are the two major families of protein factors that have effects on osteoblast proliferation and differentiation (8) . The cytokine arrays indicate that PCa-118b expressed higher levels of BMP4 and BMP6 than PCa-133, while PCa-133 expressed a higher level of FGF2, but not FGF4 and FGF9, than PCa-118b ( Figure 2B ). Both xenografts expressed very low levels of FGF6 and FGF7 ( Figure 2B ).
Other factors that are highly expressed in PCa-118b compared to PCa-133 include Gro (including α, β, and γ), IL-8, TIMP-2, SCF, IGFBP-2, MIF, MCP-1, M-CSF, sTNFR1, and sTNFRII ( Figure 2C ). On the other hand, PCa-133 expressed a higher level of BDNF compared to PCa-118b ( Figure 2C ).
BMP-4 expression in PCa-118b.
To confirm the cytokine array analysis, the levels of BMP RNA transcripts were determined by QPCR. Of BMPs 1 -9 examined, BMP4 was the most highly expressed in PCa-118b xenograft. Low levels of BMP3 and BMP6 were also detected ( Figure 2D ). None of these BMP messages were detected in PCa-133 (data not shown). Further, ELISA assays of the conditioned medium showed that BMP4 in PCa-118b was 13-fold higher than that found in PCa-133 conditioned medium, with the levels at 624.8 ± 17.3 pg/ml and 47.2 ± 4.3 pg/ml, respectively ( Figure 2D ). BMP-6 in PCa-118b was at 62.4 ± 2.6 pg/ml but too low to be detected in the PCa-133 conditioned medium ( Figure   2D ).
Effect of cytokines and conditioned medium on osteoblast proliferation and differentiation. Next, we examined the effects of these cytokines on osteoblast proliferation and/or differentiation. To improve the specificity of the measurement, primary calvarial osteoblasts isolated from a 2.3 kb collagen promoter driven luciferase reporter transgenic mice (Col-luc mice) were used (6, 9) . Previous studies have established that the luciferase reporter activity of the Col-luc osteoblasts correlated with osteoblast proliferation (9).
Treatment with 10 ng/ml FGF-2 induces an elongated spindle shape morphology, an increase in osteoblast cell number, an increase in luciferase activity, and a small but stimulates Col-luc osteoblast proliferation. In contrast, treatment with 100 ng/ml BMP-2 induces a significant increase in alkaline phosphatase activity without affecting the luciferase activity ( Figure 3A) , suggesting that BMP-2 stimulates Col-luc osteoblast differentiation.
Next, when the Col-luc osteoblasts were treated with recombinant BMP-2, -4, or -6, a significant increase (about 300% compared to the control, n=3) of alkaline phosphatase activity was observed, with no effect on luciferase activity ( Figure 3B ). In contrast, treatment with 10 ng/ml of FGF-2 or FGF-9 for three days led to an increase in luciferase activity, but a decrease in alkaline phosphatase activity ( Figure 3B ). These observations suggest that BMP2, 4 and 6 exert similar effects on osteoblast differentiation, while FGF2 and 9 exert similar effects on osteoblast proliferation.
Cytokines, including MIF ( Figure 3B ), IGFBP2, BDNF, and SCF, did not have a significant effect on luciferase or alkaline phosphatase activity of Col-luc osteoblasts (Table   1) . Gro (including Gro-α, β, and γ), IL-8, and TIMP-2, induced small but significant increases in alkaline phosphatase (Table 1) but not luciferase activity (data not shown).
These observations suggest that these cytokines may be involved, but to a lesser extent than BMP4, in the osteogenesis of the PCa-118b xenograft.
Osteoblast regulatory activities in the conditioned media of PCa-118b and PCa-133 xenografts. Next, the conditioned media from PCa-118b or -133 were examined for their effects on osteoblast differentiation or proliferation. Treatment of Col-luc calvarial osteoblasts with conditioned media from PCa-133 led to a 5-fold increase in luciferase activity, while PCa-118b xenograft only resulted in an average of 30% increase ( Figure 3C ).
In contrast, conditioned medium from PCa-118b induced about a 2-fold increase in alkaline phosphatase activity compared to that from PCa-133, which induced an average of 15% increase ( Figure 3C ). We further used a neutralizing antibody against BMP-4 to determine if BMP-4 might be involved in the increase in alkaline phosphatase activity seen in the CM of PCa-118b xenograft. The BMP-4 antibody inhibited about 40% of PCa-118b-induced increase in alkaline phosphatase activity ( Figure 3D ), while control IgG or BMP-6 antibody (data not shown) did not show an inhibitory effect. These observations suggest that BMP4 plays a significant role in PCa-118b-induced osteoblast differentiation.
BMP4 signals through BMP receptor in osteoblasts.
To examine whether PCa-118b conditioned medium activates BMP signaling in osteoblasts, we first examined its effect on Id1 promoter activity. Id1 is a direct target of the BMP pathway and its promoter contains multiple BMP-specific SMAD-binding elements (10) . The C2C12 cell line expresses BMP receptors (7) and can be induced to become osteoblasts by BMP-2. C2C12/BRE was generated by transfecting the Id1 promoter reporter into C2C12 cells (7) . When the C2C12/BRE cells were incubated with MDA-PCa-118b conditioned medium, luciferase reporter activity was increased by 5-fold, which was accompanied by a 3-fold increase in endogenous Id1 message ( Figure 4A ). In contrast, conditioned medium from PCa-133 did not stimulate Id1 promoter activity ( Figure 4B, lower panel) . LDN-193189, a small molecule inhibitor of BMP type I receptor (11) , was used to specifically inhibit BMP signaling. In osteoblasts, LDN-193189 inhibited osteoblast differentiation (Fig. 4) , but did not induce osteoblast cell death or inhibit osteoblast proliferation [data not shown and (11) Figure 4C ). These observations suggest that PCa-118b conditioned medium activated Smad5 signaling through the BMP receptors.
We further examined the effect of LDN-193189 on conditioned medium-mediated osteoblast activity. PCa-118b conditioned medium-induced alkaline phosphatase activity was significantly reduced (about 50%) by treating the osteoblasts with 100 nM LDN-193189 ( Figure 4D) , consistent with the inhibition observed with BMP4 neutralizing antibody ( Figure 3D ). LDN-193189, at a concentration of 100 nM, had no effect on osteoblast cell number (data not shown), indicating that the inhibition of alkaline phosphatase activity by LDN-193189 is not due to toxicity. Together, these results suggest that PCa-118b conditioned medium activates BMP receptor signaling in osteoblasts, and this effect is inhibited by the BMP type I receptor inhibitor LDN-193189. Figure S1 ). Consistent with a lack of response to endogenous or exogenous BMP4, PCa-118b cells did not express significant levels of BMP type I receptors, e.g., ALK2, ALK3 and ALK6 ( Figure 5B ) or BMP type II receptors, e.g., BMPR2 and ACVR2 ( Figure 5C ). In contrast, Smad5 was activated in PC-3 cells and this activation was inhibited by LDN-193189 treatment ( Figure 5A ). PC-3 cells were also found to express significant levels of BMP type I and II receptors ( Figure 5B and 5C ). Together, these results suggest that BMP-4 secreted from PCa-118b likely has minimal autocrine effects on PCa-118b cells. 
Expression of BMP receptors in
Effect of LDN-193189 on
Discussion
Although PCa bone metastasis is frequently associated with new bone formation, it is not clear whether tumor-induced osteogenesis plays a role in PCa progression in the bone. We postulated that PCa cells secrete paracrine factors that lead to an increase in bone formation, and the newly formed bone in turn secretes factors to enhance PCa progression in bone (4).
We have identified several cytokines that are differentially expressed between the osteogenic xenograft PCa-118b and non-osteogenic xenograft PCa-133. We showed that BMP4 is one of the cytokines that play a role in the osteogenesis of the PCa-118b xenograft.
Because PCa-118b does not express BMP receptors, this has allowed us to explore whether blocking BMP4-induced osteogenesis affects PCa-118b tumor growth. We showed that BMP-4 induced osteoblast differentiation was reduced by the BMP receptor kinase inhibitor LDN-193189, which resulted in a decrease in PCa-118b tumor growth. These studies thus provide evidence that tumor-induced osteogenesis mediated by paracrine BMP signaling plays a role in supporting PCa progression in bone ( Figure 6D ), and supports our previously proposed model that osteoblast activation, resulting from PCa paracrine signaling, leads to PCa cell growth in bone (4).
Our observations raised an interesting question concerning the mechanism of decreased tumor growth upon reduction of osteogenic support by LDN-193189 treatment.
We did not find significant differences in tumor cell proliferation and apoptosis, using Ki67 staining and TUNEL assays, respectively, in the control versus LDN-193189 treated PCa118b tumors (data not shown). Our interpretation is that tumor cell growth and osteoblast differentiation are interdependent during PCa-118b tumor growth. Thus, LDN-193189 treatment resulted in a proportional decrease of both types of cells. We speculate that the interdependency of tumor cells and osteoblasts involves a wide spectrum of secreted factors mediating paracrine/autocrine signaling, and that LDN-193189 partially interrupted such an interdependency. Our studies suggest that LDN-193189 treatment led to a decrease in bone formation, as reflected in serum osteocalcin levels, and this resulted in a decrease in tumor volume due to the tumor/osteoblast interdependency. 
Bone metastases of PCa predominantly result in osteoblastic lesions. However, very few cell lines or xenografts generated from human PCa bone metastasis exhibit this phenotype. MDA-PCa-118b is one of the few xenografts that elicit a strong osteogenic phenotype when implanted in SCID mice (5) . How MDA-PCa-118b induces ectopic bone formation under subcutaneous site is not clear. It is likely that MDA-PCa-118b secretes several factors that are able to stimulate osteoblast proliferation or differentiation. Indeed, in a search for these secreted factors ("prostate cancer secretome"), we showed that several factors, including BMP4 secreted by MDA-PCa-118b, are able to stimulate osteoblast differentiation. In addition, previous studies by Li et al. (5) showed that FGF9, which stimulates osteoblast proliferation, also contributes to the osteoblastic phenotype of MDAPCa-118b. Other factors yet to be identified may also be involved in the osteoblastic phenotype of MDA-PCa-118b tumor. 
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Despite the bone-forming phenotype in PCa bone metastasis, pathological analysis of the metastatic lesions in bone showed that both osteoblastic and osteolytic lesions are present in the same loci (17, 18) . Histomorphometric quantification also consistently shows changes in both bone formation and resorption within metastatic foci in iliac crest biopsy samples (19) . Consistent with the clinical observations, osteoclasts were also present in MDA-PCa-118b xenograft tumors (5). Thus, tumor-induced osteoblastic or osteolytic responses likely reflect the overall effects from factors that regulate osteoblast proliferation, differentiation, and osteoclast activation in vivo. Among the factors secreted from MDAPCa-118b xenografts, MCP-1, MCSF, and IL8 have been shown to have effects on osteoclast activation (20) (21) (22) . It is likely that other factors yet to be identified are also involved in the osteoclastic component in MDA-PCa-118b xenografts.
In conclusion, MDA-PCa-118b exhibits the unique properties that allow examination of the contribution of paracrine signaling in osteoblastic lesions of PCa. We demonstrate that BMP-4, an osteogenic factor, acts as one of the important paracrine factors. By Col-Luc PMOs were treated with cytokines for three days and alkaline phosphatase activity was measured. PMOs without treatment were used as controls and defined as 100%. 
